SUMO1P1: A Potential Drug Target Or Biomarker for Cancer (G391257)

Target Name: SUMO1P1

NCBI ID: G391257

SUMO1P1

Other Name(s): UBL6 | PIC1L | SUMO1 pseudogene 1 | UBL2

SUMO1P1: A Potential Drug Target Or Biomarker for Cancer

SUMO1P1 (UBL6) is a protein that is expressed in various tissues throughout the body. It is a key regulator of the ubiquitin-proteasome system, which is responsible for breaking down damaged or unnecessary proteins. SUMO1P1 plays a crucial role in this process by helping to ensure that damaged proteins are properly targeted for degradation.

Recent studies have suggested that SUMO1P1 may be a drug target or biomarker for various diseases, including cancer. This is because SUMO1P1 has been shown to be involved in the regulation of cellular processes that are often disrupted in cancer cells, such as the rapid growth of cells, the formation of blood vessels, and the development of tumors.

One of the key reasons for the potential targetship of SUMO1P1 to cancer is its role in the regulation of the ubiquitin-proteasome system. This system is often disrupted in cancer cells, which allows them to continue to grow and multiply uncontrollably. SUMO1P1 helps to ensure that damaged proteins are properly targeted for degradation, which is necessary for maintaining the balance of proteins in the cell. If SUMO1P1 was to be blocked or inhibited, it could potentially lead to a build-up of damaged proteins in cancer cells, which could then lead to the formation of tumors.

In addition to its role in the ubiquitin-proteasome system, SUMO1P1 has also been shown to be involved in the regulation of cell adhesion. This is important for the proper functioning of tissues and organs, and is often disrupted in diseases such as cancer. SUMO1P1 helps to ensure that cells stick together and form tissues, which is necessary for maintaining the structure and function of the body. If SUMO1P1 was to be blocked or inhibited, it could potentially lead to the loss of cell-cell adhesion, which could lead to the formation of tumors.

Another potential mechanism by which SUMO1P1 may be involved in the development of cancer is its role in the regulation of cell signaling pathways. This is important for the proper functioning of tissues and organs, and is often disrupted in diseases such as cancer. SUMO1P1 helps to ensure that signals from cell signaling pathways are properly transposed into downstream effects, which is necessary for maintaining the balance of physiological processes in the body. If SUMO1P1 was to be blocked or inhibited, it could potentially lead to the disruption of cell signaling pathways, which could then lead to the formation of tumors.

In conclusion, SUMO1P1 is a protein that plays a crucial role in the regulation of various cellular processes that are important for maintaining the balance of tissues and organs in the body. It is possible that SUMO1P1 may be a drug target or biomarker for various diseases, including cancer. Further research is needed to fully understand the role of SUMO1P1 in these processes and to develop effective treatments for these diseases.

Protein Name: SUMO1 Pseudogene 1

Functions: Ubiquitin-like protein that can be covalently attached to proteins as a monomer or as a lysine-linked polymer. Regulates the life cycle of promyelocytic leukemia nuclear bodies (PML-NBs). PolySUMO1P1/SUMO5 conjugation on 'Lys-160' of PML facilitates recruitment of PML-NB components, which enlarges PML-NB. SUMO1P1/SUMO5 also increases polySUMO2/3 conjugation of PML, resulting in RNF4-mediated disruption of PML-NBs

The "SUMO1P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SUMO1P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets